# A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

> **NCT04607148** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 144 (actual)

## Conditions studied

- Macular Degeneration, Age-Related
- Geographic Atrophy

## Interventions

- **DRUG:** Galegenimab

## Key facts

- **NCT ID:** NCT04607148
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-16
- **Primary completion:** 2022-11-14
- **Final completion:** 2022-11-14
- **Target enrollment:** 144 (ACTUAL)
- **Why stopped:** The benefit to risk balance did not support further treatment with galegenimab (FHTR2163).
- **Last updated:** 2023-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04607148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04607148, "A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04607148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*